Geneos Therapeutics has received $10.5m in series A funding from investors including its parent company Inovio Pharmaceuticals.
US-based immuno-oncology therapy developer Geneos Therapeutics has completed a $10.5m series A round that included biotechnology company Inovio Pharmaceuticals.
Venture capital firm Santé Ventures led the round that included an initial investment and further funding based on certain milestones being reached.
Geneos Therapeutics has spun out of Inovio following the round to develop personalised therapies treatments for cancer based on each patient’s own tumor mutations.
The company will develop treatments designed to direct the body’s own immune system to target…
